Abstract：
Prostate cancer is ranked second among the most common male cancers. Androgen deprivation therapy (ADT) has long been the first-line treatment and the basis for all other therapies, reducing circulating androgens to castration levels and preventing disease development. Nevertheless, ADT monotherapy may not always limit disease development, and even at low testosterone levels, hormone-sensitive prostate cancer will become castration-resistant. Recent research demonstrates that prostate cancer can have a range of potentially actionable genetic abnormalities; no medications that target these variations have yet been shown to elicit therapeutic advantages. Despite their established efficacy in the management of other cancers, advanced genetic or immunological approaches are not regularly used to treat prostate cancer patients. As a result, there is an unmet demand for medicines that offer a better chance of survival than the existing castration- resistance prostate cancer (CRPC) therapy regimens. The use of oligodeoxynucleotides (ODN) and peptides in decoy technology have been developed as novel therapeutic approaches. Decoy ODNs bind to a particular transcription factor with high affinity and may suppress gene transcription. Peptide decoys bind to specific ligands with high specificity and inhibit signaling pathways. Recent evidence supports the notion that these techniques are promising and attractive in the fight against cancer. In the present review, we discuss the use of decoy technology as a novel therapeutic approach against prostate cancer.
摘要：
前列腺癌在最常见的男性癌症中排名第二。雄激素剥夺疗法（ADT）长期以来一直是一线治疗，也是所有其他疗法的基础。将循环雄激素降低至去势水平并预防疾病发展。然而，ADT单一疗法可能并不总是限制疾病的发展，即使睾酮水平很低，激素敏感的前列腺癌将成为去势抵抗。最近的研究表明，前列腺癌可能具有一系列潜在的可操作的遗传异常；尚未显示针对这些变异的药物具有治疗优势。尽管它们在其他癌症的治疗中已经确立了疗效，先进的遗传或免疫方法不经常用于治疗前列腺癌患者。因此,与现有的去势抵抗性前列腺癌(CRPC)治疗方案相比,对提供更好生存机会的药物的需求未得到满足.在诱骗技术中使用寡脱氧核苷酸（ODN）和肽已被开发为新的治疗方法。诱骗ODN以高亲和力与特定转录因子结合并且可以抑制基因转录。肽诱饵以高特异性与特异性配体结合并抑制信号通路。最近的证据支持这样的观点，即这些技术在对抗癌症方面是有希望和有吸引力的。在本次审查中，我们讨论了使用诱饵技术作为一种新的治疗前列腺癌的方法。
